( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients

Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766

Recurring mutations found by sequencing an acute myeloid leukemia genome

Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020

Mutation in TET2 in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035

Regulation of the HIF-1α Level Is Essential for Hematopoietic Stem Cells

Takubo, K., Goda, N., Yamada, W., Iriuchishima, H., Ikeda, E., Kubota, Y., Shima, H., Johnson, R. S., Hirao, A., Suematsu, M., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.020 · Cited by 891

Synthetic lethality in cancer: mechanism exploration and therapeutic applications

Zhao, P., Wang, P., Xu, T., Chen, L., Jia, Q., & Li, M. H. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02932-x · Cited by 2

Forward Genetic Screens Identify Mechanisms of Resistance to Small-Molecule Lactate Dehydrogenase Inhibitors

Frank, A. R., Vandiver, F., & McFadden, D. G. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00663 · Cited by 2

Impact of IDH Mutations on DNA Methylation of Acute Myeloid Leukemia Related Genes: A Review Article

Bayram, D. M., Lafta, F. M., & Matti, B. F. (2024) · Journal of the Faculty of Medicine Baghdad · doi:10.32007/jfacmedbagdad.6612175 · Cited by 2

Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Cheng, Y., Wang, X., Ghosh, A., Pu, J., Carayannopoulos, L. N., & Li, Y. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2436 · Cited by 2

Exploration of the intracellular chiral metabolome in pediatric BCP-ALL: a pilot study investigating the metabolic phenotype of IgH locus aberrations

Collins, M., Gorgoglione, R., Impedovo, V., Pan, X., Sathyaseelan, C., Yi, S. S., Lodi, A., & Tiziani, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1413264 · Cited by 2

Therapy enhancing chromosome instability may be advantageous for IDH1R132H/WT gliomas

Goncharov, N. V., Baklanov, I., Gulaia, V. S., Shuliak, A. P., Lanskikh, D., Zhmenia, V., Shmelev, M. E., Shved, N. A., Wu, J., Liskovykh, M. A., et al. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf003 · Cited by 2

Knowing left from right

McCarthy, N. J. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3487 · Cited by 2

A happy cell stays home: When metabolic stress creates epigenetic advantages in the tumor microenvironment

Hanse, E. A., & Kong, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962928 · Cited by 2

Philadelphia–positive dimorphic blasts in mixed‐phenotype acute leukemia with TET 2 mutation

Jain, P., Tang, G., Huh, Y. O., Yin, C. C., Zuo, Z., Pemmaraju, N., Estrov, Z. E., & Daver, N. G. (2016) · American Journal of Hematology · doi:10.1002/ajh.24295 · Cited by 2

Genetics of glioma

Hansen, L. J., Diplas, B. H., Becher, O. J., & Yan, H. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107588721.002 · Cited by 2

AMERICAN ASSOCIATION FOR CANCER RESEARCH

(1913) · JAMA · doi:10.1001/jama.1913.04340250087035 · Cited by 2

The leukaemia epigenome targeted

Losman, J.-A. (2017) · Nature · doi:10.1038/543634a · Cited by 2

Mechanisms of Hematopoietic Stem Cell Ageing and Targets for Hematopoietic Tumour Prevention

Liao, M., & Wang, J. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1117-8_8 · Cited by 2

Mitochondrial Mutations in Cancer Progression: Causative, Bystanders, or Modifiers of Tumorigenesis?

Kurelac, I., Vidone, M., Girolimetti, G., Calabrese, C., & Gasparre, G. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1824-5_10 · Cited by 2

Cancer Metabolism

Pavlova, N. N., & Thompson, C. B. (2016) · Wiley eBooks · doi:10.1002/9781119000822.hfcm015 · Cited by 2

AML gets upSET when its dietary needs are unMet

Gallipoli, P. (2022) · Blood · doi:10.1182/blood.2022018008 · Cited by 2

Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia

Hou, H. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_5 · Cited by 1

IDH2/R140Q mutation confers cytokine-independent proliferation of TF-1 cells by activating constitutive STAT3/5 phosphorylation

Yang, J., Chen, J., Chang, J., Sun, X., Wei, Q., Cai, X., & Cao, P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01367-y · Cited by 1

Intelligent recognition of chiral alanine isomers using active terahertz low-frequency excitation

Pang, S., Su, J., Tan, K., Song, Z., Tu, S. C., Yang, J., He, Q., & Lu, M. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.145230 · Cited by 1

Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives

Rajan, A., Castro, F. R., de Godoy, L. L., Hanaoka, M. M., Türk, S., Desiderio, L. M., Stupp, R., Suyash, M., & Chawla, S. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag028 · Cited by 1

Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications

Tan, J., Wen, T., Liu, J. S., & Ru, X. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01828-0 · Cited by 1

Attempt at a systemic outlook on aging and carcinogenesis

Piwowar, M. W., Dygut, J. M., Piwowar, P., Konieczny, L., & Roterman, I. (2014) · Bio-Algorithms and Med-Systems · doi:10.1515/bams-2014-0012 · Cited by 1

Isocitrate Dehydrogenase (IDH) Mutation in Gliomas

Chesnelong, C. (2015) · Springer eBooks · doi:10.1007/978-3-319-15811-2_25 · Cited by 1

Targeted Therapy of IDH1-Mutated Tumors

Clark, O., & Grommes, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-49864-5_10 · Cited by 1

Fundamentals of cell metabolism and cancer

Devendran, R., Ramesh, V., & Gnanasekaran, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99883-3.00001-9 · Cited by 1

Cancer Metabolism

Wahl, D. R., & Venneti, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-61401-4_6 · Cited by 1

Differential metabolomic pathway analysis in Malaysian childhood acute lymphoblastic leukemia patients treated with high-dose methotrexate

Razali, R. H., Teh, L. K., Salleh, M. Z., Teh, K. H., & Ibrahim, H. M. (2024) · Pediatric Hematology Oncology Journal · doi:10.1016/j.phoj.2024.06.004 · Cited by 1

Targeting the Natural History of Clonal Hematopoiesis

McMahon, C. M. (2024) · The Hematologist · doi:10.1182/hem.v21.4.2024414 · Cited by 1

Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2 -Mutant Cholangiocarcinoma

Özgü, E., Tokat, Ü. M., Adibi, A., Bilgiç, Ş. N., Aydın, E., Tutar, O., & Demiray, M. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00652 · Cited by 1

Modèles d’oncogenèse : un monde sans fin ?

Larsen, C. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1759 · Cited by 1

Le (R)-2-hydroxyglutarate ou (R)-2HG est bien un oncométabolite

Larsen, C. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1757 · Cited by 1

Új terápiás célpont akut myeloid leukémiában: izocitrát dehidrogenáz 1 és 2 mutációk

Kövy, P., Kozma, A., Bors, A., Meggyesi, N., Ádám, E., Borsy, A., Dolgos, J., Lovas, N., Harasztdombi, J., Lakatos, V., et al. (2019) · Hematológia–Transzfuziológia · doi:10.1556/2068.2019.52.2.4 · Cited by 1

Enantiomeric Separation of 2-Hydroxyglutarate Using Chiral Mobile Phase Additives

Ohtawa, T., & Tsunoda, M. (2021) · Chromatography · doi:10.15583/jpchrom.2021.016 · Cited by 1

Abstract PL02-04: IDH mutations and tumorigenicity.

Wang, F., Travins, J. M., DeLaBarre, B., Penard‐Lacronique, V., Schalm, S. S., Hansen, E., Straley, K. S., Kernytsky, A. M., Liu, W., Gliser, C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-pl02-04 · Cited by 1

A primary patient-derived model for investigating functional heterogeneity within the human Leukemic Stem Cell CompartmentPreprint

Boutzen, H., Chan‐Seng‐Yue, M., Murison, A., Mbong, N., Wagenblast, E., Arlidge, C., Tonekaboni, S. A. M., Orouji, E., Arruda, A., Mitchell, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.01.482535 · Cited by 1

The role of prolyl hydroxylases in the function of leukaemic stem cells and the development of leukaemia

Smith, G. (2015) · Enlighten: Theses (The University of Glasgow)

Inhibitors of rogue enzyme near trials for brain and blood tumors

Williams, S. C. (2013) · Nature Medicine · doi:10.1038/nm0513-514

Epigenetic basis for the oncogenic potential of IDH mutations

Lü, C. (2013)

Twenty-fifth Annual Pezcoller Symposium: Metabolism and Tumorigenesis

Kaelin, W. G., Livingston, D. M., Loda, M. F., Vousden, K. H., & Mihich, E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2445

Myeloproliferative Neoplasms – Molecular Biology and Potential Targets for Intervention

(2014) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608058587114010005

American association for cancer research — AACR congress 2014

Vaccheli, E., Michels, J., Hadoux, J., & Lotz, J. (2014) · ONCOLOGIE · doi:10.1007/s10269-014-2414-y

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody

Bader, A. G., Brown, D., Winkler, M., Shim, E., Livi, C. B., Rakheja, D., Tan, J. C., Benson, D. G., Parekh, V., Kho, E.-Y., et al. (2014)

[Isocitrate dehydrogenase mutation in acute myeloid leukemia].

Zhang, Y., & Yang, L. (2015) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2015.01.023

Hematopoietic Stem Cell Aging and Leukemogenesis

Henry, C. J., Rozhok, A. I., & DeGregori, J. V. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1232-8_13

Altered Chromatin Signaling in Cancer

Liss, A. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802389-1.00018-6

Synthesis and Application of Cell-Permeable Metabolites for Modulating Chromatin Modifications Regulated by α-Ketoglutarate-Dependent Enzymes

Balduf, H., Pepe, A., & Kirchmaier, A. L. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6743-8_5

Metabolic Feedback Control through H3K4 Demethylation

Soloveychik, M. (2016) · TSpace (University of Toronto)

Energy Metabolism and Epigenetics

Bultman, S. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_87-1 · Cited by 1

Mitochondria Remodeling in Cancer

Dornfeld, K. J., & Skildum, A. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_9

Predictive and Prognostic Biomarkers in Myeloid Neoplasms

Pillai, R. K. (2018) · Springer eBooks · doi:10.1007/978-3-319-95228-4_31

Therapy-Induced Marrow Changes

Bhargava, P., & Whitman, J. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-32189-5_32

Integrated Metabolic Profiling and Gene Expression Analysis Reveals Therapeutic Modalities in Breast CancerPreprint

Liao, C., Glodowski, C. R., Fan, C., Liu, J., Mott, K. R., Locasale, J. W., McBrayer, S. K., DeBerardinis, R. J., Perou, C. M., & Zhang, Q. H. (2020) · Research Square · doi:10.21203/rs.3.rs-117384/v1

Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplant

Lachowiez, C. A., & Cook, R. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-53626-8_15

Genome-wide analysis of focal DNA hypermethylation in IDH -mutant AML samplesPreprint

Wilson, E. R., Helton, N., Heath, S. E., Fulton, R. S., Payton, J. E., Welch, J. S., Walter, M. J., Westervelt, P., DiPersio, J. F., Link, D. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.03.433799

R-2-HG in AML… friend or foe?

Elf, S. E., & Chen, J. (2021) · Blood Science · doi:10.1097/bs9.0000000000000067

SOHO State of the Art Updates and Next Questions: IDH Inhibition

Dragani, M., & de Botton, S. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.05.004

Updates on Acute Myeloid Leukemia Management in older patients

Otoukesh, S., Thiebaud, J. A., Marcucci, G., & Malki, M. M. A. (2021) · Trends in Transplantation · doi:10.15761/tit.1000301

Molecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasms and Its Impact on Prognosis and Management

Qasrawi, A. H., & Arora, R. (2021) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2021.06.001

Synthesis and Evaluation of 3-(Indol-3-yl)-4-(Pyrazolo[3,4-c]Pyridazin-3-yl)-Maleimides as Potent Mutant Isocitrate Dehydrogenase-1 Inhibitors

Xu, J. H., Hu, Y., Liu, X., Gao, A., Gao, L., Xu, L., Zhou, Y., Gao, J., Ye, Q., Hu, C., et al. (2021) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-021-02475-0

The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology

Benajiba, L., & Kiladjian, J. (2021) · Therapies · doi:10.1016/j.therap.2021.11.007

Research development and potential therapeutic value of m6A modification in occurrence and progression of colorectal tumors

Liu, J.-Y., Li, B., Xu, E., & Zhong, Y. (2021) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v29.i23.1373

Energy Metabolism and Epigenetics

Bultman, S. J. (2019) · Springer eBooks · doi:10.1007/978-3-319-55530-0_87

The development and application of a ChIP and MeDIP assay to determine a link between epigenetics and metabolism in ovarian cancer progression

TSE, C. (2022) · Cronfa (Swansea University) · doi:10.23889/suthesis.60060

Cancer Metabolism

Pavlova, N. N., Rao, A. D., DeBerardinis, R. J., & Thompson, C. B. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm015.pub2

Mutant IDH1 attenuates hepatic lipogenesis through PTEN dependent pathway

Zhao, Q. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.041

[Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation].

Wang, X., Bao, X., Zhang, J., Song, B., Li, M. Y., Xie, J., Shen, H., Wu, D., & Qiu, H. (2022) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2022.08.014

Data from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness

Liu, A. C. H., Cathelin, S., Yang, Y., Dai, D. L., Ayyathan, D. M., Hosseini, M., Minden, M. D., Tierens, A. M., & Chan, S. M. (2023) · doi:10.1158/0008-5472.c.6514302.v1

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness

Liu, A. C. H., Cathelin, S., Yang, Y., Dai, D. L., Ayyathan, D. M., Hosseini, M., Minden, M. D., Tierens, A. M., & Chan, S. M. (2023) · doi:10.1158/0008-5472.22433115.v1

The INDIGO trial: Precision medicine finally comes to glioma

Shi, D. D., & Kaelin, W. G. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad162

MODERN IMAGING TECHNIQUES IN THE ASSESSMENT OF MALIGNANCY IN GLIAL BRAIN TUMORS: LITERATURE REVIEW

Toleshbaev, D., Ainakulova, A., Zhakenova, Z., Akimtay, K., Myrzabaeva, G., Ramazan, A., & Zholdybay, Z. (2024) · Oncologia i radiologia Kazakhstana · doi:10.52532/2521-6414-2024-1-71-65-71

Development and Validation of UV Method for Quantitative Estimation of Olutasidenib in Pharmaceutical Dosage Form

Nandini, C., Snehitha, M. V., Meghana, A. S., Satvika, K., Anvesh, G., Babu, P. S., & Sankar, P. R. (2024) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2024.v84i03.019

A transcriptional biosensor reveals mechanisms of α-ketoglutarate signaling to chromatin

Sternisha, A. C., Li, H., Gajendra, K., Xiao, Y., Zhao, X., Traylor, J. I., Guo, L., Jun, J. H., Fleishman, M., Shipman, T., et al. (2026) · Science · doi:10.1126/science.adx8675

Leucémies aigües myéloïdes avec mutations IDH1/2

Gabellier, L., Bosetta, E., Heiblig, M., & Sarry, J. (2025) · médecine/sciences · doi:10.1051/medsci/2025045

Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment

Cheng, Y., Chen, J., Vigil, C. E., Khanzadeh, S., Rampersad, A., Prébet, T., & Li, Y. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04797-2

Lysine- R 2HGylation identified as a post-translational modification in R 2HG-elevated cancersPreprint

Zhao, Q., Huang, P., Yuan, C., Xia, P., Gu, Q., Yang, T., Li, X., Tian, R., & Yang, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.03.680013

CYP4F11 promotes lung cancer progression through the miR-195/ME2 pathway

Shi, S., Zhou, J., Luo, Q.-Y., Chen, H., Yang, J., Yang, L., Zhang, L., Zhang, H., & Yang, D. (2025) · MedScience · doi:10.1007/s11684-025-1166-y

Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib

Chien, K. S., Loghavi, S., Sasaki, K., McCue, D. A., Daver, N. G., Kadia, T. M., Ravandi, F., Short, N. J., Issa, G. C., Bravo, G. M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.001

Loss of heterozygosity exposes germline mutations in complex I and drives Warburg metabolism in oncocytic carcinoma of the thyroid

Arregui, C. D. L. C., Frank, A. R., Mun, K., Kim, J., Majmudar, K., Bishop, J. A., Lewis, C. M., Xie, Y., & McFadden, D. G. (2026) · Science Advances · doi:10.1126/sciadv.aee5417

Additional file 3 of Targeting phosphoglycerate dehydrogenase in multiple myeloma

Elsaadi, S., Steiro, I. J., Abdollahi, P., Vandsemb, E. N., Yang, R., Slørdahl, T. S., Rø, T. B., Menu, E., Sponaas, A.-M., & Børset, M. (2021) · Figshare · doi:10.6084/m9.figshare.13521195

Additional file 4 of Targeting phosphoglycerate dehydrogenase in multiple myeloma

Elsaadi, S., Steiro, I. J., Abdollahi, P., Vandsemb, E. N., Yang, R., Slørdahl, T. S., Rø, T. B., Menu, E., Sponaas, A.-M., & Børset, M. (2021) · Figshare · doi:10.6084/m9.figshare.13521198

Additional file 1 of Targeting phosphoglycerate dehydrogenase in multiple myeloma

Elsaadi, S., Steiro, I. J., Abdollahi, P., Vandsemb, E. N., Yang, R., Slørdahl, T. S., Rø, T. B., Menu, E., Sponaas, A.-M., & Børset, M. (2021) · Figshare · doi:10.6084/m9.figshare.13521189

Additional file 1 of Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Kunadt, D., Stasik, S., Metzeler, K. H., Röllig, C., Schliemann, C., Greif, P. A., Spiekermann, K., Rothenberg‐Thurley, M., Krug, U. O., Braess, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20968430

Additional file 2 of Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells

Chen, J., Yang, J., Wei, Q., Weng, L., Wu, F., Shi, Y., Cheng, X., Cai, X., Hu, C., & Cao, P. (2020) · Figshare · doi:10.6084/m9.figshare.12082356

Additional file 2 of Targeting phosphoglycerate dehydrogenase in multiple myeloma

Elsaadi, S., Steiro, I. J., Abdollahi, P., Vandsemb, E. N., Yang, R., Slørdahl, T. S., Rø, T. B., Menu, E., Sponaas, A.-M., & Børset, M. (2021) · Figshare · doi:10.6084/m9.figshare.13521192

Additional file 1 of IDH2/R140Q mutation confers cytokine-independent proliferation of TF-1 cells by activating constitutive STAT3/5 phosphorylation

Yang, J., Chen, J., Chang, J., Sun, X., Wei, Q., Cai, X., & Cao, P. (2024) · Figshare · doi:10.6084/m9.figshare.25210637

High-Q terahertz sensor based on semiconductor material with annular geometry

Lin, G. Q., & Wang, B. (2026) · Applied Physics Letters · doi:10.1063/5.0315705

Cancer biology and the principles of targeted cancer drug discovery

Davies, A., Jones, G., Krishnan, S., Krishnamoorthy, M., Maruggi, M., Kaneda, M., & Marjon, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00035-2

Caractérisation des NADPH oxydases et effet de leur inhibition dans les leucémies aigues myéloïdes

Dakik, H. (2017) · theses.fr (ABES) · doi:10.70675/c50123fez19eaz4414zaf63z4c616441a1d3

Dynamique chromatinienne lors de l'activation des enhancers au cours de la différenciation cellulaire

Mahé, E. A. (2016) · theses.fr (ABES) · doi:10.70675/daf5feb1z2f61z4e8bzb3a6za907fab675b8

Conséquences cliniques et moléculaires de la marque H3K27 me3 HIST1 dans les leucémies aigües myéloïdes sans anomalies cytogénétiques

Garciaz, S. (2018) · theses.fr (ABES) · doi:10.70675/f6bba160z544fz48b5zbb51zb5982923ed7a

Hydroxylation et halogénation directe et sélective des composés azotés en milieu superacide

Mamontov, A. (2018) · doi:10.70675/5090c791z7015z4da1zb54ez972803624458

Identification de régulateurs clés de la carcinogenèse hépatique humaine : Études clinico-pathologiques, moléculaires et fonctionnelles

Santos, A. D. (2019) · theses.fr (ABES) · doi:10.70675/50131371z9cf2z4925zad84ze1758a9a5831

Maintenance télomérique : intérêt dans le diagnostic des gliomes en lien avec le métabolisme mitochondrial

Billard, P. (2021) · theses.fr (ABES) · doi:10.70675/7d145f6az2700z4c8bzad56z3286d493fb31

Mécanismes et implications thérapeutiques de l'hypermutation dans les gliomes

Touat, M. (2020) · theses.fr (ABES) · doi:10.70675/3cf296c0z53a7z446dz8927zbeeea7661f6a

Etude in vivo du rôle du métabolisme énergétique et mitochondrial dans la résistance thérapeutique des leucémies aiguës myéloïdes

Bosc, C. (2020) · theses.fr (ABES) · doi:10.70675/e3489aa8z78d2z46e0z9435z78857025209c

KDM6 Enzymes are the Mechanistic Targets of Mutant IDH that Dictate Replication Stress SensitivityPreprint

Tsai, A. C.-Y., Lin, M. D., Puliyappadamba, V. T., Junginger, D. M., Donovan, V. G., Kaplan, E. G., Drepanos, L. M., Wakimoto, H., Cahill, D. P., Losman, J. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.14.715350

Conserved principles of central carbon partitioning in Hippo-Yorkie-driven Drosophila gut tumorsPreprint

Park, Y., Qadiri, M., Asara, J. M., Hu, Y., & Perrimon, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.05.722979

Golden rules for optimizing the diagnostic pathway of IDH-mutant tumors: bridging evidence and clinical practice in cholangiocarcinoma and adult-type diffuse gliomas

Antonelli, M., Barresi, V., Bertero, L., Daniele, B., Fassan, M., Malapelle, U., Normanno, N., Pruneri, G., & Scarpa, A. (2026) · Pathologica · doi:10.32074/1591-951x-1812

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies

Özcan, S. G., Stanko, C., Szymański, Ł., Fischer, M., Brioli, A., Zelent, A., & Schenk, T. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03512-z

Altered chromatin signaling in cancer

Okuda, Y., & Liss, A. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-19001-8.00024-6

R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis

Ye, D., Ma, S., Xiong, Y., & Guan, K. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.005 · Cited by 83

IDH Mutations, 2-Oxoglutarate-dependent Dioxygenases, and Leukemia

Kaelin, W. G. (2014) · Blood · doi:10.1182/blood.v124.21.sci-6.sci-6 · Cited by 1

Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate

Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A., Goparaju, R., Schwarzer, A., Görlich, K., Schottmann, R., Struys, E. A., Jansen, E. E. W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.71 · Cited by 50

Abstract IA02: Molecular pathogenesis of IDH mutant cancers and evolving treatment strategies

Kaelin, W. G. (2015) · Cancer Research · doi:10.1158/1538-7445.brain15-ia02

Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis

Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A. K., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F. R., et al. (2012) · Blood · doi:10.1182/blood.v120.21.770.770